ASGCT 2025
Excellos is excited to exhibit at the ASGCT Annual Meeting in New Orleans, LA!
Join over 3,400 professionals at this premier international forum for gene and cell therapy. Scientists, physicians, and advocates will gather to share the latest breakthroughs, and we’re excited to be part of the conversation.
Visit booth #1150 to see how Excellos is advancing cell and gene therapy manufacturing and therapeutic development.
RSVP to our Webinar on June 26!
Excellos360: Consolidating Clinical Correlates to Produce Predictive Outcomes of Cellular Starting Material
Please join us for this live 45 min webinar followed by Q&A
Cell Catalog Products
Excellos provides purpose-built starting material tailored to your program—from discovery to longitudinal studies. Our partnership with San Diego Blood Bank gives you access to a diverse, consented, and recallable donor pool, backed by real-world data to support your science.
A snapshot of our most popular products:
- LRS Chambers: Leukoreduction System (LRS) Chambers contain leukocytes removed during the collection process of leukapheresis materials.
- Buffy Coats: Concentrated layer of leukocytes and thrombocytes collected during centrifugal separation of blood products.
- Fresh Leukopaks: Fresh peripheral blood leukopaks are collected from healthy, consented donors and are screened for Hepatitis B, Hepatitis C, HIV-1 and HIV-2, HTLV, and Syphilis.
- Immune Cell Isolates: Pan T Cells, Natural Killer Cells, and more types isolated using MACS technology and cryopreserved for research purposes. Can provide donation-matched cell isolates or custom processes for niche cell types (e.g., Gamma Delta T Cells, Regulatory T Cells).
SABPA Recap
Our team attended SABPA’s 9th Annual Frontiers in Therapeutics and Diagnostics Forum. Key conference insights included:
- Generative AI is the hottest trend in deep learning, and showcased companies proved that artificially made-up data can produce reliable predictive algorithms.
- AI algorithms are extremely context dependent, making careful dataset selection critical.
- Company stock prices often rise following claims of having AI.
- Deep learning strategies are accelerating drug discovery by streamlining pathways to the clinic.
- AI tools optimize clinical enrollment strategies so patients get the best care and medicine can advance.
Proud Member of ARM
We’re proud to be a member of the Alliance for Regenerative Medicine, the global voice for cell and gene therapy! ARM brings together 400+ organizations to shape policy, accelerate access to therapies, and drive innovation in regenerative medicine.
Our involvement helps us bring cutting-edge knowledge, strategic partnerships, and best practices directly to your programs whether you’re navigating regulatory pathways, scaling up, or staying ahead of industry trends.
Spotlight on Excellence: Quality Assurance Team
Quality Assurance is vital for a Cell Therapy (CDMO) because it ensures the safety, efficacy, and regulatory compliance of cell therapies.
At Excellos, quality is more than a standard; it’s our foundation. Our QA and Regulatory teams ensure that every process, material, and product meets the highest GMP and GTP standards, driving compliance, consistency, and continuous improvement.
👉 Explore the full article on our website to meet the team and discover how Excellos ensures excellence in cell and gene therapy solutions.
Stay tuned for our next article coming out highlighting our agile and innovative Product Development team!
We’re excited to continue this journey with you. Stay tuned for the next edition of The Excell-ence Exclusive, and as always, feel free to reach out with any questions or thoughts. Together, we’ll continue advancing the future of cell therapy!
